Literature DB >> 8103403

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

H Donis-Keller1, S Dou, D Chi, K M Carlson, K Toshima, T C Lairmore, J R Howe, J F Moley, P Goodfellow, S A Wells.   

Abstract

Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are dominantly inherited conditions which predispose to the development of endocrine neoplasia. Evidence is presented that sequence changes within the coding region of the RET proto-oncogene, a putative transmembrane tyrosine kinase, may be responsible for the development of neoplasia in these inherited disorders. Single strand conformational variants (SSCVs) in exons 7 and 8 of the RET proto-oncogene were identified in eight MEN 2A and four FMTC families. The variants were observed only in the DNA of individuals who were either affected or who had inherited the MEN2A or FMTC allele as determined by haplotyping experiments. The seven variants identified were sequenced directly. All involved point mutations within codons specifying cysteine residues, resulting in nonconservative amino acid changes. Six of the seven mutations are located in exon 7. A single mutation was found in exon 8. Variants were not detected in four MEN 2B families studied for all exon assays available, nor were they detectable in 16 cases of well documented sporadic medullary thyroid carcinoma or pheochromocytoma that were tested for exon 7 variants. Coinheritance of the mutations with disease and the physical and genetic proximity of the RET proto-oncogene provide evidence that RET is responsible for at least two of the three inherited forms of MEN 2. Neither the normal function, nor the ligand of RET are yet known. However, its apparent involvement in the development of these inherited forms of neoplasia as well as in papillary thyroid carcinoma suggest an important developmental or cell regulatory role for the protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103403     DOI: 10.1093/hmg/2.7.851

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  257 in total

1.  Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease.

Authors:  G Fitze; M Schreiber; E Kuhlisch; H K Schackert; D Roesner
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

Review 2.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

3.  The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.

Authors:  J Oriola; I Halperin; F Rivera-Fillat; H Donis-Keller
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

Review 4.  Hirschsprung disease, associated syndromes, and genetics: a review.

Authors:  J Amiel; S Lyonnet
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

5.  Mixed medullary and follicular carcinoma of the thyroid. On the search for its histogenesis.

Authors:  X Matias-Guiu
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 6.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 7.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

8.  Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma.

Authors:  I Torrente; F Arturi; L D'Aloiso; A Colosimo; A De Luca; E Ferretti; D Russo; E Chiefari; D Scarpelli; M Bisceglia; B Dallapiccola; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

9.  Targeting RET Kinase in Neuroendocrine Prostate Cancer.

Authors:  Halena R VanDeusen; Johnny R Ramroop; Katherine L Morel; Song Yi Bae; Anjali V Sheahan; Zoi Sychev; Nathan A Lau; Larry C Cheng; Victor M Tan; Zhen Li; Ashley Petersen; John K Lee; Jung Wook Park; Rendong Yang; Justin H Hwang; Ilsa Coleman; Owen N Witte; Colm Morrissey; Eva Corey; Peter S Nelson; Leigh Ellis; Justin M Drake
Journal:  Mol Cancer Res       Date:  2020-05-27       Impact factor: 5.852

10.  How is the Human Genome Project doing, and what have we learned so far?

Authors:  M S Guyer; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.